Charles River has inked a partnership deal with Distributed Bio that will give the CRO’s clients access to antibody libraries and integrated antibody optimization technologies.
Under the agreement, the two companies aim to create an end-to-end platform for therapeutic antibody discovery and development, they said.
San Francisco-based Distributed Bio provides computationally optimized libraries that can generate more than 5,000 unique hits against every antigen tested. Its platform can speed the discovery process to 3 to 4 months, it said.
“Distributed Bio’s technology, coupled with Charles River’s deep scientific strength in drug discovery and early-stage development, ensure that our portfolio is truly next generation,” Birgit Girshick, Charles River’s EVP of Discovery and Safety, said in a statement. “This combination provides our clients with Distributed Bio’s ability to discover new antibodies, then proceed seamlessly from hit to clinical candidate faster than before.”
Earlier this year, in two separate agreements, Pfizer and Boehringer Ingelheim signed agreements for drug discovery using Distributed Bio’s library Super Human 2.0.